Lifesci Capital Predicts Immunovant Q2 Earnings

Key Points

• Lifesci Capital predicts Immunovant will report a Q2 2026 earnings per share (EPS) of ($0.70), coinciding with estimates of ($2.81) EPS for the fiscal year 2026.
• Immunovant's latest earnings announcement showed an EPS of ($0.60), surpassing the consensus estimate of ($0.69) by $0.09.
• Analyst ratings for Immunovant vary, with three hold ratings, eight buy ratings, and one strong buy, leading to a consensus target price of $35.20.

Immunovant, Inc. (NASDAQ:IMVT - Free Report) - Stock analysts at Lifesci Capital issued their Q2 2026 earnings per share estimates for Immunovant in a research note issued on Monday, August 11th. Lifesci Capital analyst S. Slutsky expects that the company will post earnings of ($0.70) per share for the quarter. The consensus estimate for Immunovant's current full-year earnings is ($2.69) per share. Lifesci Capital also issued estimates for Immunovant's Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.70) EPS and FY2026 earnings at ($2.81) EPS.

Several other analysts have also weighed in on the company. Citigroup reissued a "buy" rating on shares of Immunovant in a report on Monday, August 11th. UBS Group lifted their target price on Immunovant from $17.00 to $18.00 and gave the company a "neutral" rating in a research note on Monday, July 28th. Bank of America decreased their target price on Immunovant from $33.00 to $30.00 and set a "buy" rating for the company in a research note on Tuesday, August 12th. JPMorgan Chase & Co. decreased their target price on Immunovant from $40.00 to $37.00 and set an "overweight" rating for the company in a research note on Tuesday, August 12th. Finally, The Goldman Sachs Group upgraded Immunovant to a "hold" rating and set a $18.00 target price for the company in a research note on Thursday, July 10th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Immunovant currently has a consensus rating of "Moderate Buy" and an average target price of $35.20.

Immunovant Stock Up 0.1%

Immunovant stock traded up $0.02 during midday trading on Thursday, hitting $15.22. The stock had a trading volume of 1,781,359 shares, compared to its average volume of 1,321,870. Immunovant has a 12 month low of $12.72 and a 12 month high of $34.47. The business has a fifty day moving average price of $16.50 and a 200 day moving average price of $16.90.

Immunovant (NASDAQ:IMVT - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.09. During the same period in the prior year, the business earned ($0.60) earnings per share.

Insider Activity at Immunovant

In other news, insider Michael Geffner sold 2,385 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $18.15, for a total transaction of $43,287.75. Following the completion of the transaction, the insider directly owned 221,825 shares in the company, valued at approximately $4,026,123.75. The trade was a 1.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CTO Jay S. Stout sold 2,805 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $18.15, for a total value of $50,910.75. Following the completion of the sale, the chief technology officer owned 204,919 shares of the company's stock, valued at $3,719,279.85. This trade represents a 1.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,869 shares of company stock valued at $140,384. Insiders own 1.80% of the company's stock.

Institutional Investors Weigh In On Immunovant

A number of institutional investors have recently added to or reduced their stakes in IMVT. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Immunovant by 11.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,603 shares of the company's stock valued at $106,000 after buying an additional 675 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Immunovant by 2.6% in the second quarter. The Manufacturers Life Insurance Company now owns 36,124 shares of the company's stock valued at $578,000 after buying an additional 900 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of Immunovant by 14.9% in the second quarter. Ameritas Investment Partners Inc. now owns 6,976 shares of the company's stock valued at $112,000 after buying an additional 904 shares in the last quarter. Strs Ohio bought a new position in shares of Immunovant in the first quarter valued at $27,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Immunovant by 4.1% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,641 shares of the company's stock valued at $683,000 after buying an additional 1,670 shares in the last quarter. 47.08% of the stock is currently owned by institutional investors and hedge funds.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.